ImmunityBio Stock Jumps on $100M Financing Deal

ImmunityBio Secures $100 Million for Global Expansion

ImmunityBio, Inc. (NASDAQ:IBRX) announced it has secured $100 million in new financing, causing its shares to rise by 8%. The funding is intended to support the global commercialization of its cancer therapy, ANKTIVA, and advance its broader immunotherapy pipeline.

Details of the Financing Agreement

The financing package includes $75 million in non-dilutive funding from Oberland Capital under an existing Revenue Interest Purchase Agreement. This transaction increases the total committed capital under the agreement to $375 million. The terms remain largely the same, with a minor increase in the royalty payback rate.

Additionally, Nant Capital, an affiliate of Executive Chairman Patrick Soon-Shiong, converted $25 million of debt into equity. This was executed by issuing 4.6 million shares of common stock, which reduces the company's outstanding debt under a promissory note due in December 2024.

Impact on Market and Strategy

This capital infusion strengthens ImmunityBio's financial position as it scales its operations globally. The financing follows a series of recent regulatory approvals for ANKTIVA, its treatment for non-muscle invasive bladder cancer. Approvals have been granted by the U.S. FDA, the UK's MHRA, and the European Commission, covering approximately 34 countries.

The deal was viewed positively by investors, as the significant non-dilutive portion allows the company to raise capital without substantially diluting existing shareholder value. The funds provide critical resources to capitalize on market opportunities following these key regulatory milestones.

Summary and Outlook

The successful $100 million financing positions ImmunityBio to execute its global expansion strategy for ANKTIVA. With regulatory hurdles cleared in major markets, the focus shifts to commercial execution and supply chain management. Market watchers will be closely monitoring the company's sales performance and progress in its ongoing immunotherapy pipeline development.

FAQ

Q: What is the total financing ImmunityBio announced?
A: ImmunityBio announced a total of $100 million in financing transactions.

Q: What will the new funds be used for?
A: The proceeds will support the global commercial expansion of its cancer therapy, ANKTIVA, and advance its immunotherapy pipeline following recent regulatory approvals.

Q: How did the market react to the news?
A: ImmunityBio's (IBRX) stock shares rose by 8% following the announcement.

Source: Investing.com